

Amendment to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

1. (Currently Amended) A formulation for nasal application comprising:
 - a) at least one sexual hormone drug;
 - b) at least one lipophilic or partly lipophilic carrier, comprising at least one oil in an amount of between 60% and 98% by weight of the formulation; and
 - c) a A compound or a mixture of compounds having surface tension decreasing activity, an amount effective for *in situ* generation of an emulsion upon contact of the formulation with water.
2. (Original) The formulation according to claim 1, wherein the lipophilic carrier comprises an oil.
3. (Currently Amended) The formulation according to claim 2, wherein said oil is a vegetable oil.
4. (Original) The formulation according to claim 3, wherein said oil is castor oil.
5. (Currently Amended) The formulation according to claim 2, wherein the amount of oil comprises ~~between 30% and 98% by weight, preferably between 60 and 98% by weight, more preferably between 75% and 95% by weight, even more preferably between 85% and 95% by weight and most preferably around 90% by weight~~ of the formulation.
6. (Previously Presented) The formulation according to claim 1, wherein component (c) comprises at least one surfactant selected from the group consisting of lecithin, fatty acid ester of polyvalent alcohols, of sorbitanes, of polyoxyethylensorbitans, of polyoxyethylene, of sucrose, of polyglycerol and/or at least one humectant selected from the group consisting of sorbitol, glycerine, polyethylene glycol, and macrogol glycerol fatty acid ester, or a mixture thereof.
7. (Original) The formulation according to claim 6, wherein component (c) comprises an oleoyl macrogolglyceride or a mixture of oleoyl macrogolglycerides.
8. (Currently Amended) The formulation according to claim 6, wherein component (c) is comprised within the formulation in an amount of from 1 to 20% by weight, ~~preferably 1 to 10% by weight, more preferably 1 to 5% by weight, and most preferably at around 4% by weight.~~

9. (Previously Presented) The formulation according to claim 1, further comprising a viscosity regulating agent.

10. (Original) The formulation according to claim 9, wherein said viscosity regulating agent comprises a thickener or gelling agent selected from the group consisting of cellulose and cellulose derivatives, polysaccharides, carbomers, polyvinyl alcohol, povidone, colloidal silicon dioxide, cetyl alcohols, stearic acid, beeswax, petrolatum, triglycerides and lanolin, or a mixture thereof.

11. (Currently Amended) The formulation according to claim 10, wherein said viscosity ~~increasing~~ regulating agent is colloidal silicon dioxide.

12. (Previously Presented) The formulation according to claim 9, wherein the viscosity regulating agent is comprised within the formulation in an amount of from 0.5 to 10% by weight, ~~preferably 0.5 to 5% by weight, more preferably 1 to 3% by weight, and most preferably at around 3% by weight.~~

13. (Previously Presented) The formulation according to claim 1, wherein the sexual hormone drug is testosterone.

14. (Currently Amended) The formulation according to claim 1, wherein the sexual hormone drug is comprised within the formulation in an amount of from 0.5 to 6% by weight, ~~preferably 2 to 4% by weight, more preferably 0.5 to 2% by weight, and most preferably at around 2% by weight.~~

15. (New) The formulation of claim 5, wherein the amount of oil comprises between 85% and 95% by weight of the formulation.

16. (New) The formulation of claim 8, wherein component (c) is comprised within the formulation in an amount of from 1 to 10% by weight.

17. (New) The formulation of claim 8, wherein component (c) is comprised within the formulation in an amount of from 1 to 5% by weight.

18. (New) The formulation of claim 9, wherein the viscosity regulating agent is comprised within the formulation in an amount of from 0.5 to 5% by weight.

19. (New) The formulation of claim 9, wherein the viscosity regulating agent is comprised within the formulation in an amount of from 1 to 3% by weight.

20. (New) The formulation of claim 1, wherein the sexual hormone drug is comprised within the formulation in an amount of from 2 to 4% by weight.

21. (New) The formulation of claim 1, wherein the sexual hormone drug is comprised within the formulation in an amount of from 0.5 to 2% by weight.